Best Stock Report – Penny Stock Newsletter Tracking

Welcome to Market Pulse’s online newsletter. Market Pulse is a small-cap investor’s first stop Web page. Each month, our user-friendly Web site profiles new and emerging companies that have excellent potential. We also feature quotes, charts, SEC filings, news headlines, previous profiles of featured companies and other valuable information that is easily accessed. We recommend that anyone investing perform his or her own due diligence.
Market Pulse will be issuing its current profile for Arrayit Corporation (OTCBB: ARYC) to the investment community very soon! Stay Tuned For Frequent Updates at www.market-pulse.com.
Arrayit Corporation (OTCBB: ARYC) Investors need to be watching Arrayit Corporation (OTCBB: ARYC) this AM! Arrayit Corporation is engaged in the development, manufacture, and marketing of life science technologies and integrated systems for the analysis of genetic variation, biological function, and diagnostics. Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The company’s products include microarrayers, microarray scanners, DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray instruments, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms. Arrayit’s worldwide business position leverages the company’s widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The company is also involved in the import, export, and distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy applications. It has research collaboration with The Parkinson’s Institute of Sunnyvale to discover biomarkers for Parkinson’s disease. ARYC recently announced that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics with patented technology that allows the screening and monitoring of up to 80,000 patient samples on a single microscope slide, rather than testing one patient per slide as is currently practiced. Their corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as their highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for their customers in the research, pharmaceutical, diagnostic, and health care markets! ARYC just had excellent news out in a press release before today’s opening bell announcing that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution! Investors should be watching this one closely!

Press Release
Source: Arrayit Corporation
Mark Schena, PhD, Positions Arrayit Corporation to Enter Molecular Diagnostics Using VIP Technology
Single Laboratory Test Can Screen up to 100,000 Patients
SUNNYVALE, CA–(MARKET WIRE)–June 24, 2009 — Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that its patented testing procedure, sold under the trade name Variation Identification Platform (VIP), is ready for distribution and use.
Created by pioneer and Arrayit President, Dr. Mark Schena, VIP is the world’s key microarray diagnostics patent that allows clinicians to test up to 100,000 patients against a single disease state health condition by printing that bio-information on a single slide and then drawing a diagnosis for each individual patient. Arrayit is now positioned to move this revolutionary technology from research to clinical applications and beyond.
In 1995, Dr. Schena and colleagues published the first paper on microarrays in the premier scientific journal, Science, introducing microarrays to the world as a new scientific technology. His work rapidly led to a new field of discovery that uses microarrays to investigate both genes and proteins in research and diagnostics. Acknowledged by his peers for the importance of these accomplishments, Dr. Schena was proclaimed the Father of Microarray Technology by The Scientist, a broadly read scientific journal, in 2003.
Today microarrays are used in more than 100,000 laboratories in 50 countries to explore complicated questions in biology, chemistry, agriculture and medicine. The microarray field to date has produced 550,000 scientific publications. The commercial expansion of microarray technologies has created a multi-billion dollar research market with over 200 companies that produce ancillary products and services.
Dr. Schena has authored five foundational books and has published more than 30 important papers. Dr. Schena has organized symposia and course work, chaired societal meetings and promoted the expansion of microarray technology — accruing over half a million travel miles to speak to audiences of PhDs, MDs and life science professionals.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Contact: Arrayit Corporation Tel: +1-408-744-1331 Email: investorinfo@arrayit.com Web: www.arrayit.com
For additional information please call 800.290.8935 or visit www.market-pulse.com.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.
Market Pulse All Rights Reserved.
© Copyright 2009
————————————————————
Disclaimer/Disclosure
The publisher of this email is Market Pulse, which is an independent electronic online newsletter that is owned by Market Pulse LLC (MP).
Market Pulse (MP) is an investor or public relations firm which concentrates on promoting awareness among brokers, investors, and others in the investment community of small and micro-cap companies which otherwise have difficulty receiving coverage in the financial press. MP typically performs that service by profiling the companies on its Web sites, or by direct mailings to its database of members of the investment community.
Companies featured on Market Pulse’s online newsletter pay consideration, which may include cash and/or shares of stock, to MP for dissemination of company information and, in some cases, for consulting services. When MP receives shares as compensation for investor relations, public relations, or consulting services for a featured company, MP may sell part or all of any such shares during the period in which MP is performing such services. MP’s services for a company may cause the company’s stock price to increase, in which event MP would make a profit when it sells its stock in the company. In addition, MP’s selling of a company’s stock may have a negative effect on the market price of the stock. All statements and expressions are the opinion of the companies featured and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. MP is not a registered investment advisor or a broker dealer. While it is MP’s goal to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation, investments in the companies reviewed are considered to be a high risk and use of the information provided is at the investor’s sole risk. MP shall not be liable for any loss, damage, or expense of any kind resulting from the purchase of securities of a profiled company. MP may act as a consultant to the companies reviewed in this publication and may be remunerated by these companies or its shareholders for investor relation services.
Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP’s analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted. MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company’s filings with the SEC and various press releases issued by the company.
The information that MP relies on is generally provided by the featured companies and also may include information from outside sources and interviews conducted by MP. While MP believes all sources of the information to be reliable, MP makes no representation or warranty as to the accuracy of the information provided. Investors should not rely solely on the information contained in this publication. Rather, investors should use the information contained in this publication as a starting point for doing additional independent research on the featured companies. Factual statements in this publication are made as of the date stated and are subject to change without notice. Nothing in this publication shall constitute a representation or warranty that there has been no change in the affairs of the company since the date of MP’s profile of the company. MP and/or its officers, directors, or affiliates have received compensation for the dissemination of information on the companies which are the subject of profiles and/or may have, from time to time, a position in the securities with the intent to sell the securities mentioned herein. The profiles in the publication are believed to be reliable; however the publisher disclaims any and all liability as to the completeness or accuracy of the information contained in any profile and for any omissions of material facts from such profile. The profiles within this publication are not to be construed as offers to purchase securities in the companies which may be the subject of such profiles pursuant to federal or state law or the laws of any foreign jurisdiction. MP or MP’s affiliates, agents, and/or relatives thereof may have interests or positions in equity securities of the companies reviewed in this email, some or all of which may have been acquired prior to the dissemination of this report, and may increase or decrease these positions at any time. MP has been compensated, in connection with its profile of Arrayit Corporation, fifty thousand shares of Arrayit Corporation’s common stock by a third party shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares of Arrayit Corporation’s shares for a total purchase price of twenty three thousand eight hundred twenty dollars. To date, MP has not sold any of these shares.
MP may be retained as a consultant for one to twelve months to companies that we feature. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or The Financial Industry Regulatory Authority (“FINRA”) at www.finra.org.